Triglycerides, like cholesterol, are lipids. They come from fats carried by food or produced by the human body. Depending on the cause, the accumulation of triglycerides in blood is associated with an increased risk of cardiovascular and pancreatic illnesses, and other complications. Now, by blocking the expression of a certain gene in patients, University of Montreal researchers state that they have decreased the concentration of triglycerides in their blood. The gene in question codes for the apoC-III protein and when blocked the amount of triglycerides in their blood was decreased even in various severe forms of hypertriglyceridemia and regardless of any treatment patient was receiving. The opensource study is published in the New England Journal of Medicine.
Previous studies show that triglycerides, like cholesterol, are lipids. They come from fats carried by food or produced by the human body. Depending on the cause, the accumulation of triglycerides in blood is associated with an increased risk of cardiovascular and pancreatic illnesses, and other complications. The current study suggests that the protein apoC-III plays a key role in the management of triglycerides.
Although rare forms of genetic triglyceride accumulation exist, for which there are few effective treatments, hypertriglyceridemia is the one most often associated with frequent health issues, such as obesity or diabetes. Last December, the same team demonstrated blocking the expression of the gene that encodes apoC-III led to major relief of triglyceridemia in patients suffering a rare and extreme form of hypertriglyceridemia, which in turn opened the door for the identification of unexpected mechanisms that govern blood fat.
The results demonstrate apoC-III’s important contribution to the complex mechanisms by which the body manages blood fat. The team state that decoding mechanisms opens the door to precise, individual interventions for the prevention of residual risk associated with the various causes of severe hypertriglyceridemia. They go on to surmise that the results of these studies enable the acceleration of research targeting better understanding and control of the risk trajectory associated with various forms of severe hypertriglyceridemia. The researchers conclude that the results are promising in terms of the prevention of the risk associated with the accumulation of fat in blood.
Source: Université de Montréal
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.